Join Now

Author Archives: Natalie Themm

Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide

By Natalie Themm | Published December 11, 2025

TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform.

Posted in BioUtah News | Tagged | Comments Off on Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

By Natalie Themm | Published December 11, 2025

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).

Posted in BioUtah News | Tagged | Comments Off on Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

By Natalie Themm | Published December 11, 2025

New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

CLENE ANNOUNCES STATISTICALLY SIGNIFICANT ALS BIOMARKER RESULTS SUPPORTING ACCELERATED APPROVAL PATHWAY FOR CNM-AU8®

By Natalie Themm | Published December 11, 2025

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8.

Posted in BioUtah News | Tagged | Comments Off on CLENE ANNOUNCES STATISTICALLY SIGNIFICANT ALS BIOMARKER RESULTS SUPPORTING ACCELERATED APPROVAL PATHWAY FOR CNM-AU8®

Canary Speech Earns Microsoft Solutions Partner: Healthcare AI Certified Software Designation

By Natalie Themm | Published December 11, 2025

Prestigious recognition validates Canary Speech’s leadership in healthcare-focused AI voice technology and its proven interoperability with the Microsoft Cloud

Posted in BioUtah News | Tagged | Comments Off on Canary Speech Earns Microsoft Solutions Partner: Healthcare AI Certified Software Designation

bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia

By Natalie Themm | Published December 4, 2025

bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia

Posted in BioUtah News | Tagged | Comments Off on bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia

PolarityBio Completes Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers

By Natalie Themm | Published December 4, 2025

PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development possible

Posted in BioUtah News | Tagged | Comments Off on PolarityBio Completes Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

By Natalie Themm | Published December 4, 2025

Milestone enables immediate production of SiN/PEEK custom devices

Posted in BioUtah News | Tagged | Comments Off on SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

5 Trends to Expect From Vocal Biomarker Technology in 2026

By Natalie Themm | Published December 4, 2025

By Henry O’Connell, CEO and co-founder of Canary Speech   Vocal biomarker data has come a long way in a short amount of time. No longer relegated to the pages of science fiction, the power of the human voice to assist in diagnoses is established fact. Providers already possess technological platforms that make informed care […]

Posted in BioUtah News | Tagged | Comments Off on 5 Trends to Expect From Vocal Biomarker Technology in 2026

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

By Natalie Themm | Published November 13, 2025

100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation

By Natalie Themm | Published November 13, 2025

Salt Lake City, UT –Wednesday November, 5th 2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT) will be presenting new preclinical data demonstrating that focused ultrasound (FUS) using proprietary phase-shift microbubbles, NanoBlate (MVT-101), can selectively ablate brain tumors and open the blood-brain barrier (BBB) in targeted regions, potentially enabling safer, more precise, and […]

Posted in BioUtah News | Tagged | Comments Off on New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation

Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs

By Natalie Themm | Published November 13, 2025

Collaboration bridges home and hospital, creating a secure pathway for pediatric insights to be managed and shared.

Posted in BioUtah News | Tagged | Comments Off on Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs

A Special Thanks To Our Legacy and Platinum Elite Members